Trials / Completed
CompletedNCT01308619
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxycycline | doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning |
| OTHER | Placebo | Placebo, oral, one capsule daily in the morning |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2011-03-04
- Last updated
- 2022-08-01
- Results posted
- 2014-08-05
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01308619. Inclusion in this directory is not an endorsement.